NCT06663137Phase 2Recruiting

A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC

Study sponsor: Relmada Therapeutics, Inc. · RLMD

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-11Estimated
Enrollment · participants70Estimated
Source updated2026-09-02Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Primary completion date changed

Before: Aug 2025. After: Nov 2027.

Check registry source